Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
ConditionPrimary CNS Lymphoma
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorJames Rubenstein
About this trial
This phase I trial evaluates the feasibility of using hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing patients with primary central nervous system lymphoma. This trial aims to see whether MRI using hyperpolarized carbon-13 pyruvate is safe and useful for detecting central nervous system lymphoma and evaluating response to treatment.
Eligibility criteria
Qualifiers
For Patients in Cohort 1: Histologically proven relapsed PCNSL who have evidence of evaluable disease based on a prior MR scan, or relapsed CNS lymphoma: measurable disease based on MRI is defined as gadolinium enhancement of a CNS lymphoma lesion (at least one centimeter (cm) diameter).
For Patients in Cohort 2: Histologically proven newly diagnosed PCNSL who will receive standard treatment with high-dose methotrexate, temozolomide plus rituximab (MT-R). These criteria will ensure validity of this study in terms of safety, evaluation of clinically and radiographically relevant disease.
Patients must be > 18 years old and with a life expectancy > 12 weeks.
Patients are eligible provided the participant had histologic confirmation of CNS non-Hodgkin lymphoma (NHL), DLBCL-type.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Hyperpolarized pyruvate (13C)
- Magnetic resonance imaging (MRI)
Treatment groups
26 Participants
are divided into 2 treatment groupsSponsors and collaborators
James Rubenstein
Lead sponsor
University of California, San Francisco
Sponsor institution
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov